← Leaderboards
Joseph P Vacanti
Massachusetts General Hospital
$2,421,180
Attributed
$3,818,496
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $744.1K · FY2011–14$1M$750K$500K$250K$0
'11
'12
'13
'14
Funding mix
By agency
NIH$3,818,496 · 2
By mechanism
R01$3,818,496 · 2
Top collaborators
- Darrell N. Kotton4 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Alan C Mullen$4,280,887
- Andrew M Tager$6,891,119
- Shiv Subramaniam Pillai$21,368,359
- Roy Soberman$7,702,299
- Yaakov Nahmias$727,483
Others in their field
Top investigators on “Biological Models”
- Dennis R. Burton · Scripps Research Institute$262,954,131
- Leonard Freedman · Leidos Biomedical Research, Inc.$255,277,443
- David Heimbrook · Leidos Biomedical Research, Inc.$221,978,438
- Richard A Gibbs · Baylor College Of Medicine$208,738,665
- Garret A Fitzgerald · University Of Pennsylvania$142,078,043
- Deborah J Donnell · Fred Hutchinson Cancer Center$127,641,689
Research focus
Biological ModelsTissue EngineeringSheepAlveolarArtificial LungAutologousAnimalsBaseCell ProliferationBiomaterial Development /PreparationBiomedical EngineeringBiopsyBioreactorsBlood Vessel ProsthesisCell AdhesionBlood VesselsCell Differentiation ProcessCell LineAutologous TransplantationCellsCell TransplantationCellular BiologyChronic Obstructive Airway DiseaseAmerican
Grant awards (7)
Bioengineering of Transplantable Humanized Lungs from iPS Cells$744,106
R01 · FY2014 · HL
Bioengineering of Transplantable Humanized Lungs from iPS Cells$727,688
R01 · FY2013 · HL
Bioengineering of Transplantable Humanized Lungs from iPS Cells$649,164
R01 · FY2012 · HL
Bioengineering of Transplantable Humanized Lungs from iPS Cells$673,674
R01 · FY2011 · HL
TISSUE ENGINEERING OF BLOOD VESSEL SUBSTITUTES$341,288
R01 · FY2002 · HL
TISSUE ENGINEERING OF BLOOD VESSEL SUBSTITUTES$341,288
R01 · FY2001 · HL
TISSUE ENGINEERING OF BLOOD VESSEL SUBSTITUTES$341,288
R01 · FY2000 · HL